NCT03866382 2026-04-16Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNational Cancer Institute (NCI)Phase 2 Recruiting314 enrolled